CY1122505T1 - Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn - Google Patents

Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn

Info

Publication number
CY1122505T1
CY1122505T1 CY20191101021T CY191101021T CY1122505T1 CY 1122505 T1 CY1122505 T1 CY 1122505T1 CY 20191101021 T CY20191101021 T CY 20191101021T CY 191101021 T CY191101021 T CY 191101021T CY 1122505 T1 CY1122505 T1 CY 1122505T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
crohn
pathology
antibodies
Prior art date
Application number
CY20191101021T
Other languages
English (en)
Inventor
Jill Giles-Komar
David M. Knight
David Peritt
Bernhard Scallon
David Shealy
Original Assignee
Centocor Research & Development, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122505(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Research & Development, Inc. filed Critical Centocor Research & Development, Inc.
Publication of CY1122505T1 publication Critical patent/CY1122505T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η παρούσα εφεύρεση αναφέρεται σε τουλάχιστον ένα νεωτερικό αντι-IL-12 αντίσωμα, συμπεριλαμβανομένων απομονωμένων νουκλεϊκών οξέων, τα οποία κωδικοποιούν τουλάχιστον ένα αντι-IL-12 αντίσωμα, IL-12, φορείς, κύπαρα ξενιστές, διαγονιδιακά ζώα ή φυτά, σε μεθόδους για την παρασκευή και την χρήση αυτών, συμπεριλαμβανομένων θεραπευτικών συνθέσεων, μεθόδων και συσκευών.
CY20191101021T 2000-08-07 2019-10-02 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn CY1122505T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US22335800P 2000-08-07 2000-08-07
US23682700P 2000-09-29 2000-09-29
US09/920,262 US6902734B2 (en) 2000-08-07 2001-08-01 Anti-IL-12 antibodies and compositions thereof
PCT/US2001/024720 WO2002012500A2 (en) 2000-08-07 2001-08-07 Anti-il-12 antibodies, compositions, methods and uses
EP10184116.1A EP2305817B1 (en) 2000-08-07 2001-08-07 Anti-il-12 antibodies, compositions, methods and uses
EP09006396.7A EP2090657B1 (en) 2000-08-07 2001-08-07 Anti-IL-12 antibodies, compositions, methods and uses
EP01959598A EP1309692B1 (en) 2000-08-07 2001-08-07 Anti-il-12 antibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
CY1122505T1 true CY1122505T1 (el) 2020-05-29

Family

ID=27397221

Family Applications (7)

Application Number Title Priority Date Filing Date
CY20091100601T CY1109149T1 (el) 2000-08-07 2009-06-09 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY2009007C CY2009007I2 (el) 2000-08-07 2009-06-12 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY20171100525T CY1118901T1 (el) 2000-08-07 2017-05-18 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY20171101269T CY1119650T1 (el) 2000-08-07 2017-12-05 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY2018010C CY2018010I1 (el) 2000-08-07 2018-03-19 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY20191101021T CY1122505T1 (el) 2000-08-07 2019-10-02 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY2020003C CY2020003I1 (el) 2000-08-07 2020-01-16 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CY20091100601T CY1109149T1 (el) 2000-08-07 2009-06-09 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY2009007C CY2009007I2 (el) 2000-08-07 2009-06-12 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY20171100525T CY1118901T1 (el) 2000-08-07 2017-05-18 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY20171101269T CY1119650T1 (el) 2000-08-07 2017-12-05 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY2018010C CY2018010I1 (el) 2000-08-07 2018-03-19 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2020003C CY2020003I1 (el) 2000-08-07 2020-01-16 Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn

Country Status (33)

Country Link
US (15) US6902734B2 (el)
EP (5) EP3178934B1 (el)
JP (4) JP4731094B2 (el)
KR (1) KR100823576B1 (el)
CN (2) CN101550190B (el)
AR (1) AR030134A1 (el)
AT (1) ATE431412T1 (el)
AU (2) AU2001281137B2 (el)
BR (1) BRPI0113109B8 (el)
CA (1) CA2418961C (el)
CL (1) CL2009000575A1 (el)
CY (7) CY1109149T1 (el)
DE (2) DE122009000025I1 (el)
DK (4) DK2305817T3 (el)
EA (1) EA006673B1 (el)
ES (4) ES2624502T3 (el)
FR (1) FR09C0021I2 (el)
HK (1) HK1135991A1 (el)
HR (1) HRP20030087B1 (el)
HU (1) HU228009B1 (el)
IL (1) IL154325A (el)
LT (6) LT2305817T (el)
LU (3) LU91584I2 (el)
ME (1) ME00326B (el)
MX (1) MXPA03001229A (el)
MY (1) MY133377A (el)
NL (1) NL300390I2 (el)
NO (3) NO330903B1 (el)
NZ (2) NZ535865A (el)
PT (4) PT3178934T (el)
RS (1) RS50477B (el)
SI (4) SI2305817T1 (el)
WO (1) WO2002012500A2 (el)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
AU2003218432A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1576011B1 (en) * 2002-10-30 2009-08-12 Genentech, Inc. Inhibition of il-17 production
CN102584997A (zh) * 2002-11-08 2012-07-18 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
MXPA05004955A (es) * 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
PT1648998E (pt) * 2003-07-18 2014-11-04 Amgen Inc Agentes de ligação específica ao factor de crescimento do hepatócito
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
WO2005079837A1 (en) * 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
DK1839120T3 (da) * 2004-12-21 2013-11-11 Janssen Biotech Inc Vektorer baseret på Anti-IL-12-antistoffer, værtsceller og fremgangsmåder til fremstilling og anvendelser
JP2008523842A (ja) * 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
AU2005330672B2 (en) * 2005-04-18 2011-07-28 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
US7700739B2 (en) * 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
WO2007137328A1 (en) * 2006-05-26 2007-12-06 Apollo Life Sciences Limited An isolated il-12 molecule or chimeric molecules thereof
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2009225797A1 (en) 2008-03-18 2009-09-24 Abbvie Inc. Methods for treating psoriasis
BRPI0908312A2 (pt) * 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
KR20110093799A (ko) * 2008-10-20 2011-08-18 아보트 러보러터리즈 Ｉｌ-12에 결합하는 항체 및 이의 정제 방법
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
KR101811886B1 (ko) 2009-05-05 2017-12-22 노비뮨 에스 에이 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
RU2012114854A (ru) * 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
TW201309330A (zh) * 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013170168A1 (en) * 2012-05-10 2013-11-14 Bioatla Llc Multi-specific monoclonal antibodies
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
CN107614012A (zh) * 2015-04-24 2018-01-19 加利福尼亚大学董事会 使用工程化的细胞检测、监测或治疗疾病或病况的系统及制备和使用它们的方法
CN109071648B (zh) * 2015-10-23 2022-07-19 辉瑞有限公司 抗il-2抗体及其组合物和用途
CA3019164A1 (en) * 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2018024770A1 (en) 2016-08-03 2018-02-08 Formycon Ag Production of biosimilar ustekinumab in cho cells
KR20190078648A (ko) * 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US11597762B2 (en) 2016-12-14 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
TR201808283A2 (tr) * 2018-06-11 2018-07-23 Centurion Ilac San Ve Tic A S Sulu farmasöti̇k etenersept bi̇leşi̇mi̇
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
SI3883606T1 (sl) 2018-09-24 2023-10-30 Janssen Biotech, Inc. Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11548941B2 (en) 2018-11-20 2023-01-10 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
JP2022518208A (ja) 2019-01-15 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
JP2022518250A (ja) 2019-01-23 2022-03-14 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎の治療方法で使用するための抗ｔｎｆ抗体組成物
MA55284A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
JP2022525179A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための産生方法
JP2022526493A (ja) * 2019-03-18 2022-05-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
BR112021024425A2 (pt) 2019-06-03 2022-01-18 Janssen Biotech Inc Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática
BR112021024401A2 (pt) 2019-06-03 2022-04-19 Janssen Biotech Inc Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
KR20220038775A (ko) * 2019-07-30 2022-03-29 아케소 바이오파마, 인크. 항-인간 p40 단백질 도메인 항체 및 이의 용도
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021126435A1 (en) 2019-12-20 2021-06-24 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
US20220073603A1 (en) * 2020-07-30 2022-03-10 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US122464A (en) 1872-01-02 Improvement in cheese-hoops
US941234A (en) 1909-02-25 1909-11-23 Frank De Clercq Syrup-percolator.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
GB8517895D0 (en) 1985-07-16 1985-08-21 Technology Licence Co Ltd Monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
JP2980626B2 (ja) 1988-01-11 1999-11-22 ゾーマ・コーポレーション ペクチン酸リアーゼのシグナル配列を含む新規プラスミドベクター
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2002607C (en) 1988-11-10 2004-01-27 Gordon G. Wong Natural killer stimulatory factor
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
CA2064915C (en) 1989-08-07 2001-05-29 Deborah A. Rathjen Tumour necrosis factor binding ligands
EP0494955B1 (en) 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
DK0790255T3 (da) 1989-12-22 2007-11-26 Hoffmann La Roche Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
TW212184B (el) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2084307A1 (en) 1990-06-01 1991-12-02 Cetus Oncology Corporation Compositions and methods for identifying biologically active molecules
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ATE189124T1 (de) 1991-07-02 2000-02-15 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4207475A1 (de) 1992-03-10 1993-09-16 Goldwell Ag Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
WO1994008038A1 (en) 1992-10-02 1994-04-14 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
SK51695A3 (en) 1992-10-19 1995-11-08 Dura Pharma Inc Dry powder medicament inhaler
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
AU5883694A (en) 1993-01-19 1994-08-15 Glaxo Group Limited Device
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
EP0804561B1 (en) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
EP0614989A1 (en) 1993-02-17 1994-09-14 MorphoSys AG A method for in vivo selection of ligand-binding proteins
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0652227B1 (en) * 1993-04-30 1998-02-25 Tokyo Tanabe Company Limited Method of purifying hydrophobic polypeptide
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2178669T3 (es) 1994-03-07 2003-01-01 Medarex Inc Moleculas biespecificas que tienen utilidad clinica.
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
WO1995029239A2 (en) 1994-04-22 1995-11-02 Corixa Corporation Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
CA2219361C (en) * 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
PL327616A1 (en) 1996-01-03 1998-12-21 Glaxo Group Ltd Inhaler
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19624387C2 (de) 1996-06-19 1999-08-19 Hatz Motoren Kaltstartvorrichtung
DK0826695T3 (da) 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6086876A (en) 1997-02-07 2000-07-11 The Wistar Insitute Methods and compositions for the inhibition of interleukin-12 production
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
EP1049717B1 (en) * 1998-01-23 2007-03-21 F. Hoffmann-La Roche Ag Antibodies against human il-12
ATE305506T1 (de) 1998-12-09 2005-10-15 Protein Design Labs Inc Verwendung von il-12 antikörpern zur behandlung von psoriasis
KR20120091477A (ko) 1999-03-25 2012-08-17 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1506302A4 (en) 2002-05-23 2006-02-08 Cognis Ip Man Gmbh CANDIDA TROPICALIS BLOCKED BY OXIDATION BETA NON REVERSIBLE
DE102007030072A1 (de) 2007-06-29 2009-01-02 BSH Bosch und Siemens Hausgeräte GmbH Elektrischen Antriebseinrichtung für ein Wasserführendes Haushaltsgerät
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
JP5155355B2 (ja) 2010-04-07 2013-03-06 レノボ・シンガポール・プライベート・リミテッド 無線基地局の自律的な負荷調整が可能な無線端末装置
US9619256B1 (en) 2012-06-27 2017-04-11 EMC IP Holding Company LLC Multi site and multi tenancy
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
US9205258B2 (en) 2013-11-04 2015-12-08 ElectroCore, LLC Nerve stimulator system
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
LUC00145I2 (el) 2021-08-13
NO2011023I2 (no) 2011-10-04
US9409984B2 (en) 2016-08-09
PT2090657T (pt) 2017-05-03
CY2020003I2 (el) 2020-05-29
PT2305817T (pt) 2017-10-26
EA200300137A1 (ru) 2003-08-28
BRPI0113109B8 (pt) 2021-05-25
EP2305817A2 (en) 2011-04-06
NZ524145A (en) 2004-11-26
AU8113701A (en) 2002-02-18
CY1118901T1 (el) 2018-02-14
CY1119650T1 (el) 2018-04-04
US20190248884A1 (en) 2019-08-15
LU91584I2 (fr) 2009-09-10
NL300390I2 (en) 2010-03-01
SI2090657T1 (sl) 2017-06-30
FR09C0021I1 (el) 2009-09-25
LTPA2009002I1 (lt) 2020-03-25
CN101550190A (zh) 2009-10-07
JP2004527212A (ja) 2004-09-09
LT3178934T (lt) 2019-09-25
IL154325A0 (en) 2003-09-17
US20030124123A1 (en) 2003-07-03
US20140178295A1 (en) 2014-06-26
CL2009000575A1 (es) 2009-07-17
EP2090657A2 (en) 2009-08-19
US9676848B2 (en) 2017-06-13
DE60138711D1 (de) 2009-06-25
YU9303A (sh) 2006-05-25
EP2090657A3 (en) 2011-12-28
WO2002012500A3 (en) 2003-01-03
MXPA03001229A (es) 2003-10-15
DK2090657T3 (en) 2017-06-06
US20050196838A1 (en) 2005-09-08
US11078267B2 (en) 2021-08-03
MEP44408A (en) 2011-02-10
NO330903B1 (no) 2011-08-15
CY2009007I1 (el) 2012-01-25
HRP20030087A2 (en) 2005-10-31
SI3178934T1 (sl) 2019-10-30
DE122009000025I1 (de) 2009-09-17
ES2747573T3 (es) 2020-03-10
EP2305817A3 (en) 2011-12-28
US20080090290A1 (en) 2008-04-17
CA2418961A1 (en) 2002-02-14
JP2012025779A (ja) 2012-02-09
ES2624502T3 (es) 2017-07-14
HK1135991A1 (zh) 2010-06-18
EP3178934A1 (en) 2017-06-14
US8329171B2 (en) 2012-12-11
US20050002937A1 (en) 2005-01-06
HU228009B1 (en) 2012-08-28
US6902734B2 (en) 2005-06-07
WO2002012500A2 (en) 2002-02-14
CN1468309A (zh) 2004-01-14
ES2323760T3 (es) 2009-07-24
LUC00066I1 (el) 2018-03-23
DK1309692T3 (da) 2009-06-15
NZ535865A (en) 2007-01-26
AU2001281137B2 (en) 2007-03-15
US7063964B2 (en) 2006-06-20
US20200062841A1 (en) 2020-02-27
PL360258A1 (en) 2004-09-06
CY2020003I1 (el) 2020-05-29
US20090274707A1 (en) 2009-11-05
EP3597752A1 (en) 2020-01-22
LTC2305817I2 (lt) 2021-04-26
US20050214293A1 (en) 2005-09-29
US7166285B2 (en) 2007-01-23
KR100823576B1 (ko) 2008-04-21
LTPA2020001I1 (lt) 2020-02-10
CY2018010I2 (el) 2018-09-05
FR09C0021I2 (fr) 2010-06-11
LUC00066I2 (el) 2018-05-25
LU91584I9 (el) 2019-01-03
HRP20030087B1 (en) 2012-07-31
US8084233B2 (en) 2011-12-27
NO20030614L (no) 2003-04-02
BRPI0113109B1 (pt) 2017-02-07
US20120063998A1 (en) 2012-03-15
CA2418961C (en) 2009-11-03
CY2018010I1 (el) 2018-09-05
KR20030034133A (ko) 2003-05-01
NO2020005I1 (no) 2020-03-11
EP1309692A2 (en) 2003-05-14
JP6076303B2 (ja) 2017-02-08
EP2090657B1 (en) 2017-03-01
ES2647220T3 (es) 2017-12-20
US8703141B2 (en) 2014-04-22
DK3178934T3 (da) 2019-09-30
LTC1309692I2 (lt) 2020-06-25
RS50477B (sr) 2010-03-02
ATE431412T1 (de) 2009-05-15
IL154325A (en) 2010-12-30
US20050112127A1 (en) 2005-05-26
SI1309692T1 (sl) 2009-08-31
PT3178934T (pt) 2019-10-14
AR030134A1 (es) 2003-08-13
EP1309692B1 (en) 2009-05-13
US7887807B2 (en) 2011-02-15
LT2305817T (lt) 2017-11-27
EP2305817B1 (en) 2017-09-27
CN101550190B (zh) 2016-04-13
JP2015061835A (ja) 2015-04-02
US20130064760A1 (en) 2013-03-14
US20180334500A1 (en) 2018-11-22
US20170029496A1 (en) 2017-02-02
US7279157B2 (en) 2007-10-09
JP4731094B2 (ja) 2011-07-20
CY2009007I2 (el) 2012-01-25
DK2305817T3 (en) 2017-12-04
LT2090657T (lt) 2017-07-25
US10259867B2 (en) 2019-04-16
JP2011173884A (ja) 2011-09-08
CY1109149T1 (el) 2012-01-25
US10519231B2 (en) 2019-12-31
EA006673B1 (ru) 2006-02-24
NO20030614D0 (no) 2003-02-07
ME00326B (me) 2011-05-10
PT1309692E (pt) 2009-05-21
LTPA2018007I1 (lt) 2018-04-10
NL300390I1 (en) 2009-07-01
US7560247B2 (en) 2009-07-14
MY133377A (en) 2007-11-30
US20110082190A1 (en) 2011-04-07
BR0113109A (pt) 2004-02-03
HUP0302378A2 (hu) 2003-10-28
SI2305817T1 (en) 2018-02-28
NO2011023I1 (no) 2011-10-17
EP3178934B1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1120739T1 (el) Αντισωματα αντι-il-6, συνθεσεις, μεθοδοι και χρησεις
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
TW200716745A (en) Anti-TNF antibodies, compositions, methods and uses
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
CY1116547T1 (el) Anti-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1110755T1 (el) Αντι-διπλα αντισωματα ιντεγκρινης, συνθεσεις, μεθοδοι και χρησεις
MY171238A (en) Anti-tnf antibodies, compositions, methods and uses